Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis

BACKGROUND: Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain. METHODS: We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweek...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Ting, Zhang, Feng, Yao, Qing-min, Liu, Yan-xia, Zhu, Xiao-juan, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439710/
https://www.ncbi.nlm.nih.gov/pubmed/28531181
http://dx.doi.org/10.1371/journal.pone.0177950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439710/
https://www.ncbi.nlm.nih.gov/pubmed/28531181
http://dx.doi.org/10.1371/journal.pone.0177950

Ejemplares similares